An interventional study of Sirtuin activators and Placebo in Obesity & Overweight, sponsored by Poznan University of Life Sciences. Recruiting at 1 site in Poland. Open to female participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Poznan University of Life Sciences · Not applicable, Interventional, and Other
The goal of this clinical trial is to learn if the six-month supplementation with sirtuin activators can affect metabolism in 40-to-65-year old women with increased body weight. The main questions it aims to answer are:
Does sirtuin activators affect lipid and carbohydrate metabolism? Does sirtuin activators affect oxydative stress, immune functions and cell ageing?
Researchers will compare sirtuin activators to a placebo (a look-alike substance that contains no drug) to see if drug sirtuin activators works to improve metabolic status.
Participants will:
Take sirtuin activators or a placebo every day for 6 months. Visit the university once every 3 months for checkups and tests.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's planned enrollment of 120 is above the median of 67 across 9,006 interventional studies indexed under Obesity.
Browse Obesity studies →Poznan University of Life Sciences is the lead sponsor of 25 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sirtuin activators supplementation for 6 months, daily dose of 1278 mg, taken twice a day in a capsulated form. Daily dose will contain: resveratrol - 500 mg, leucin - 467 mg, Epigallocatechin gallate - 100 mg, quercetin - 100 mg, curcuminoids - 100 mg, niacin 10.7 mg. Daily number of capsules will be 2 x 2 = 4.
Dietary Supplement: Sirtuin activators
Placebo will be an inactive substance (maltodextrin) provided in the same-looking capsules as sirtuin activators. Placebo will be administered twice a day, daily number of capsules will be 2 x 2 = 4.
Dietary Supplement: Placebo
Sirtuin acitivators supplementation for 6 months
Placebo supplementation for 6 months
Concentrations of blood lipids
Total cholesterol, Triacyglycerols, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesteroll
Time frame: 6 months, two measurements: at month 0 and 6
Blood glucose concentrations
Blood glucose concentration
Time frame: 6 months, two measurements: at month 0 and 6
Ageing biomarkers: transcription level of the p16INK4a gene in peripheral blood mononuclear cells
transcription level of the p16INK4a gene in peripheral blood mononuclear cells
Time frame: 6 months, two measurements: at month 0 and 6
Ageing biomarkers: telomere lenght
telomere lenght measured in DNA isolated from whole blood
Time frame: 6 months, two measurements: at month 0 and 6
Ageing biomarkers: SA beta galactosidase activity
SA beta galactosidase activity
Time frame: 6 months, two measurements: at month 0 and 6
Oxidative stress
activities of oxidative stress enzymes in blood
Time frame: 6 months, two measurements: at month 0 and 6
Body mass
Measured in kg
Time frame: 6 months, two measurements: at month 0, 3 and 6
Body composition
Body composition will include percent body fat and lean body mass measured with air displacement plethysmography
Time frame: 6 months, two measurements: at month 0, 3 and 6
Waist and hips circumference
Measured in cm
Time frame: 6 months, two measurements: at month 0, 3 and 6
Genotype analyisis of the Sirt1 gene
Nucleotite variants at certain genomic position will be analysed
Time frame: baseline
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Poznan University of Life Sciences